Pillar Biosciences Achieves Milestone with Unique CPT Code
Pillar Biosciences, a leader in Decision Medicine™, has recently received a unique CPT® Proprietary Laboratory Analyses (PLA) code 0523U from the American Medical Association. This milestone was achieved for their FDA-approved oncoReveal™ CDx pan-cancer solid tumor in vitro diagnostic (IVD) NGS kit. This recognition marks a significant step forward in the realm of personalized cancer diagnosis and treatment.
Understanding oncoReveal™ CDx
OncoReveal™ CDx represents an advanced NGS-based IVD kit utilizing proprietary SLIMamp technology. This innovative approach allows for the detection of single nucleotide variants (SNVs), as well as insertions and deletions, across 22 genes. The kit is designed to work with DNA isolated from formalin-fixed paraffin-embedded (FFPE) tumor samples, making it highly applicable in clinical settings.
FDA Clearance and Applications
The oncoReveal™ CDx assay kit has been cleared by the FDA and employs the Illumina MiSeq™ Dx platform, affirming its reliability and effectiveness in producing accurate genomic data. Its primary purpose is to provide comprehensive tumor mutation profiling, thereby assisting qualified healthcare professionals in making informed decisions based on established oncological guidelines.
Role in Targeted Therapies
Notably, oncoReveal™ CDx has been recognized as a companion diagnostic tool, identifying patients who may benefit from specific targeted therapies. In particular, it has shown significant potential for use in patients with non-small cell lung cancer (NSCLC) who could benefit from EGFR TKI therapy, as well as patients with colorectal cancer (CRC) in conjunction with drugs like ERBITUX® and VECTIBIX®.
Statements from Leadership
Brian Wright, the Chief Marketing Officer of Pillar Biosciences, expressed pride in achieving this major milestone. He mentioned, "We have enabled rapid and affordable NGS testing to be performed locally in any NGS lab, which is a game-changer for patients and clinicians alike. We are dedicated to creating highly precise, actionable testing solutions that improve treatment outcomes for cancer patients worldwide." This dedication underscores Pillar's commitment to expanding access to cutting-edge diagnostic tools.
About Pillar Biosciences
Pillar Biosciences stands at the forefront of Decision Medicine™, employing advanced next-generation sequencing (NGS) technology to enhance the treatment selection process for cancer patients. Their innovative testing solutions leverage SLIMamp® and PiVAT® technologies, significantly reducing diagnostic costs while improving access to complex NGS testing for practitioners and patients globally. With over 20 distinct NGS testing kits available, Pillar Biosciences is continually expanding its offerings, with several panels under development to meet the growing needs of the healthcare community.
The company is headquartered in Massachusetts and emphasizes its mission to improve healthcare outcomes through precise, patient-centered diagnostic solutions.
Frequently Asked Questions
What is the significance of the CPT code received by Pillar Biosciences?
The CPT code simplifies billing and coding for healthcare providers using the oncoReveal™ CDx kit, enhancing accessibility and insurance reimbursement.
How does oncoReveal™ CDx work?
This kit uses advanced NGS technology to analyze tumor DNA for mutations, aiding in targeted therapy selection for cancer patients.
What cancers can oncoReveal™ CDx help detect?
It provides mutation profiling for multiple solid tumors, making it a versatile tool for oncologists treating various cancer types.
Who can use oncoReveal™ CDx?
Qualified healthcare professionals in oncology can utilize the kit to profile tumors and guide treatment decisions effectively.
Where is Pillar Biosciences headquartered?
The company is based in Massachusetts, where they develop their innovative diagnostic solutions for cancer.
